MENU
NEWSLETTERS
MENU
SECTIONS
OTHER
CLASSIFIEDS
CONTACT US / FAQ
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Alvotech - Ordinary Shares (NQ:ALVO)

3.740 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jun 4, 2026 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Alvotech - Ordinary Shares

< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
News headline image
Alvotech Nears Inflection Point With 5 U.S. Biosimilars Targeted by Year-End ↗
Alvotech (NASDAQ:ALVO) is at an “inflection point” after more than a decade of investment in its biosimilar platform, Founder and Executive Chairman Róbert Wessman said at the Jefferies Global... 
Via MarketBeat
News headline image
Alvotech announces resubmission of U.S. Biologics License Applications for AVT05, a proposed biosimilar to Simponi® and Simponi Aria®, and AVT06, a proposed biosimilar to Eylea®
From Alvotech
Via GlobeNewswire
News headline image
Main Results of 2026 Annual and Extraordinary General Meeting
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to present at upcoming investor conferences in June
From Alvotech
Via GlobeNewswire
Alvotech (NASDAQ:ALVO) Q1 2026 Results Miss Estimates, Shares Drop Over 9% as Revenue and EPS Fall Short ↗
Via Chartmill
Alvotech (NASDAQ:ALVO) Reports Q4 Revenue Beat but Significant EPS Miss, Stock Falls on Weak Guidance ↗
Via Chartmill
News headline image
Alvotech (ALVO) Q4 2025 Earnings Transcript ↗
Alvotech (ALVO) Q4 2025 Earnings Transcript 
Via The Motley Fool
Topics Bonds
News headline image
Alvotech Plans June FDA Resubmissions, Sees Biosimilar Approvals by Year-End ↗
Alvotech (NASDAQ:ALVO) Chief Strategy Officer Balaji Prasad said the biosimilar developer is preparing to resubmit three biologics license applications to the U.S. Food and Drug Administration in June... 
Via MarketBeat
News headline image
Alvotech Announces Completion of FDA Surveillance Inspection at Reykjavik Facility
From Alvotech
Via GlobeNewswire
News headline image
Alvotech (ALVO) Q1 2026 Earnings Transcript ↗
Alvotech (ALVO) Q1 2026 Earnings Transcript 
Via The Motley Fool
News headline image
Alvotech Q1 2026 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Announces a Change in its Executive Team
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Financial Results for the First Quarter of 2026
From Alvotech
Via GlobeNewswire
Wondering what's happening in today's after-hours session? ↗
Via Chartmill
News headline image
Alvotech Files Annual Report with the SEC
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Q4 2025 and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
Alvotech to Report Fourth Quarter and Full Year 2025 Financial Results
From Alvotech
Via GlobeNewswire
News headline image
ALVO INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Alvotech
From Kirby McInerney LLP
Via GlobeNewswire
News headline image
Why Is ALVO Stock Rising Pre-Market Today? ↗
The company reported that the study showed AVT80, its biosimilar candidate to Entyvio, met all primary endpoints. 
Via Stocktwits
News headline image
Alvotech Announces Positive Top-Line Results from Pivotal Pharmacokinetic Study for Proposed Biosimilar to Entyvio®
From Alvotech
Via GlobeNewswire
News headline image
Alvotech enters supply and commercialization agreements for Canada and Australia & New Zealand covering multiple biosimilar candidates
From Alvotech
Via GlobeNewswire
News headline image
Alvotech Secures Settlement Agreement in Global Markets for its Biosimilar to Eylea® 2mg
From Alvotech
Via GlobeNewswire
News headline image
The High-Stakes Balancing Act: Johnson & Johnson Braces for Q4 Earnings Amid Patent Cliffs and MedTech Expansion
As the opening bell approaches on January 21, 2026, all eyes on Wall Street are fixed on Johnson & Johnson (NYSE: JNJ), which is set to report its fourth-quarter and full-year 2025 financial results.... 
Via MarketMinute
Topics Bankruptcy Earnings Economy
News headline image
Bragar Eagel & Squire, P.C. Continues Investigations into Alvotech and Beyond Meat on Behalf of Stockholders and Encourages Investors to Contact the Firm
From Bragar Eagel & Squire
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Alvotech announces planned CEO succession and leadership transition
From Alvotech
Via GlobeNewswire
News headline image
ALVO Investigation: Investors Encouraged to Contact Kirby McInerney LLP
From Kirby McInerney LLP
Via Business Wire
News headline image
ALVO Investor News: If You Have Suffered Losses in Alvotech (NASDAQ: ALVO), You Are Encouraged to Contact The Rosen Law Firm About Your Rights
From The Rosen Law Firm PA
Via GlobeNewswire
News headline image
Alvotech Secures Term Loan Facility of USD 100 Million
From Alvotech
Via GlobeNewswire
< Previous 1 2 3 4 5 6 7 8 9 10 11 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.
TOP
Email a Story